Cytek Enterprise Value Over E B I T D A from 2010 to 2024
CTKB Stock | USD 6.03 0.01 0.17% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (64.23) | Current Value (61.02) | Quarterly Volatility 259.85070339 |
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek main balance sheet or income statement drivers, such as Net Interest Income of 5.5 M, Interest Income of 8 M or Depreciation And Amortization of 9.7 M, as well as many exotic indicators such as Price To Sales Ratio of 6.07, Dividend Yield of 0.0 or PTB Ratio of 3.3. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
Cytek | Enterprise Value Over E B I T D A |
Latest Cytek Biosciences' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Cytek Biosciences over the last few years. It is Cytek Biosciences' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
Timeline |
Cytek Enterprise Value Over E B I T D A Regression Statistics
Arithmetic Mean | 443.82 | |
Geometric Mean | 366.64 | |
Coefficient Of Variation | 58.55 | |
Mean Deviation | 222.73 | |
Median | 610.86 | |
Standard Deviation | 259.85 | |
Sample Variance | 67,522 | |
Range | 675 | |
R-Value | (0.81) | |
Mean Square Error | 24,451 | |
R-Squared | 0.66 | |
Significance | 0.0002 | |
Slope | (47.34) | |
Total Sum of Squares | 945,313 |
Cytek Enterprise Value Over E B I T D A History
About Cytek Biosciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Cytek Biosciences income statement, its balance sheet, and the statement of cash flows. Cytek Biosciences investors use historical funamental indicators, such as Cytek Biosciences's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may use each financial statement separately, they are all related. The changes in Cytek Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytek Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytek Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Enterprise Value Over EBITDA | (64.23) | (61.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out the analysis of Cytek Biosciences Correlation against competitors. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Cytek Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.09) | Revenue Per Share 1.497 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.